Unveiling IGLVIV-66-1: A Potential Drug Target and Biomarker for Hematological Disorders

Target Name: IGLVIV-66-1

NCBI ID: G84097

IGLVIV-66-1

Other Name(s): immunoglobulin lambda variable (IV)-66-1 (pseudogene) | Immunoglobulin lambda variable (IV)-66-1 (pseudogene)

Unveiling IGLVIV-66-1: A Potential Drug Target and Biomarker for Hematological Disorders

Unveiling the Potential Drug Target and Biomarker IGLVIV-66-1: A Pseudogene for the Treatment of Hematological Disorders

Introduction

Hematological tumors are one of the malignant tumors with the highest incidence rate and highest fatality rate in the field of cancer, posing a serious threat to human health. The occurrence of hematopoietic system tumors is closely related to the imbalance of the immune system, and immunoglobulin light chain (Ig light chain) mutation (IGLVIV-66-1), as a new type of gene mutation, may cause a variety of immune cell dysfunction and have negative effects on the blood. Serious impact on system health. Currently, treatments for IGLVIV-66-1 are limited, and some patients have poor prognosis. Therefore, studying IGLVIV-66-1 as a drug target or biomarker has important clinical significance.

Biological significance of IGLVIV-66-1

IGLVIV-66-1 is an immunoglobulin light chain genetic mutation caused by a single nucleotide change. The mutation of IGLVIV-66-1 will cause about 15% of the immunoglobulin light chain to mutate, thus affecting the normal function of the immune system. Mutation of IGLVIV-66-1 can lead to a variety of immune cell dysfunction, such as clonal expansion of B cells and T cells, decreased memory cell function, decreased cytokine production, etc., thus affecting immune surveillance and clearance functions, leading to hematological tumors. The risk of occurrence increases.

The relationship between IGLVIV-66-1 and hematological tumors

Multiple studies have shown that IGLVIV-66-1 mutations are closely related to the occurrence of various hematological tumors, such as Hodgkin lymphoma, systemic mesothelioma, multiple myeloma, etc. For example, studies have found that IGLVIV-66-1-positive patients have a significantly increased incidence of hematological tumors compared with the normal population, and the tumor burden of IGLVIV-66-1-positive patients is significantly higher than that of the normal population. In addition, the variation of IGLVIV-66-1 is also closely related to the clinical manifestations and disease prognosis of hematological tumors, such as disease progression rate, disease recurrence rate, survival rate, etc.

Therapeutic targets and biomarkers of IGLVIV-66-1

Since existing treatments have limited therapeutic effect on IGLVIV-66-1, studying IGLVIV-66-1 as a drug target or biomarker has important clinical significance. First, IGLVIV-66-1 has great potential as a drug target. Through the intervention of IGLVIV-66-1, the normal function of the immune system can be restored, thereby improving the killing ability of tumor cells and improving the clinical manifestations and survival rate of tumor patients. At present, the therapeutic targets for IGLVIV-66-1 mainly include immunomodulators, anti-tumor drugs and biological agents. Among them, immunomodulators such as sodium formate and BCG are considered effective treatments, and anti-tumor drugs such as cyclophosphamide and cisplatin also have certain therapeutic effects.

IGLVIV-66-1 has important clinical significance as a biomarker. By detecting the expression level of IGLVIV-66-1, the patient's immune status can be evaluated and provide a reference for immunotherapy. In addition, analysis of the gene expression level of IGLVIV-66-1 can reveal the molecular mechanisms related to IGLVIV-66-1 and tumor occurrence and development, providing a basis for molecular classification and precise treatment of tumors.

in conclusion

In summary, IGLVIV-66-1, as a new type of gene mutation, is closely related to the occurrence of hematological tumors. By studying the biological significance, therapeutic targets and biomarkers of IGLVIV-66-1, it is expected to provide new ideas and methods for the treatment of hematological tumors and improve the clinical manifestations and survival rates of patients.

Protein Name: Immunoglobulin Lambda Variable (IV)-66-1 (pseudogene)

The "IGLVIV-66-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLVIV-66-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets